Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00307_DB00872> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00307_DB00872 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00307_DB00872 label "DDI between Bexarotene and Conivaptan - Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification. [drugbank_resource:DB00307_DB00872]" assertion.
- drugbank_resource:DB00307_DB00872 identifier "drugbank_resource:DB00307_DB00872" assertion.
- drugbank_resource:DB00307_DB00872 title "DDI between Bexarotene and Conivaptan - Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification." assertion.